Develop a US market access landscape in a rare disease to support commercial decision making and forecast assumptions
A large biopharmaceutical company required insight on the current market access landscape in a rare disease, as well as feedback on a pipeline product that will launch as a second-to-market agent in the rare disease.
Certara designed primary research with US payers to understand the rare disease market in three ways:
- Today’s access landscape
- Future access landscape with one new product launching
- Future access landscape with two new products launching
Certara delivered a comprehensive report outlining favorable access for the pipeline product at a price above current standard of care’s wholesale acquisition cost (WAC), and identified endpoints that a second-to-market product could leverage to differentiate from the first-to-market product.
